Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer.

Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic

Read the full 314 word article

User Sign In